Protara Therapeutics (TARA) Share-based Compensation (2013 - 2026)

Protara Therapeutics (TARA) has reported Share-based Compensation for 14 consecutive years, with $11.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Share-based Compensation rose 9520.66% year-over-year to $11.6 million; the TTM figure through Mar 2026 stood at $11.6 million (up 687.62% YoY), while the FY2025 annual figure was $5.9 million, up 61.34% from the prior year.
• Share-based Compensation advanced to $11.6 million in Q1 2026 per TARA's latest filing, from $1.0 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $11.6 million in Q1 2026 and bottomed at $111000.0 in Q2 2024.
• Historically, Share-based Compensation has averaged $1.6 million across 5 years, with a median of $1.1 million in 2024.
• Annual changes were most pronounced in 2024 — Share-based Compensation plunged 91.41% — and 2026, when it soared 9520.66%.
• Protara Therapeutics' Share-based Compensation stood at $1.4 million in 2022, then rose by 1.54% to $1.5 million in 2023, then slumped by 70.8% to $424000.0 in 2024, then surged by 145.99% to $1.0 million in 2025, then surged by 1016.11% to $11.6 million in 2026.
• Business Quant data shows TARA's Share-based Compensation at $11.6 million in Q1 2026, $1.0 million in Q4 2025, and $851000.0 in Q3 2025.